Compare SMID & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | ACHV |
|---|---|---|
| Founded | 1960 | N/A |
| Country | United States | United States |
| Employees | N/A | 28 |
| Industry | Building Materials | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.6M | 726.5M |
| IPO Year | 1996 | 2018 |
| Metric | SMID | ACHV |
|---|---|---|
| Price | $24.23 | $7.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.67 |
| AVG Volume (30 Days) | 12.0K | ★ 1.5M |
| Earning Date | 04-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.76 | N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $93,446,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $48.90 | ★ N/A |
| Revenue Growth | ★ 19.03 | N/A |
| 52 Week Low | $24.63 | $2.62 |
| 52 Week High | $43.00 | $8.64 |
| Indicator | SMID | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 31.81 | 44.86 |
| Support Level | N/A | $5.84 |
| Resistance Level | $31.47 | $8.61 |
| Average True Range (ATR) | 1.22 | 0.37 |
| MACD | -0.14 | -0.14 |
| Stochastic Oscillator | 1.81 | 1.45 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.